Nuwellis' Pediatric Segment Hits 50% of U.S. Revenue in 2025
Event summary
- Nuwellis' pediatric category generated ~50% of total U.S. revenue in 2025, marking a strategic growth milestone.
- The company's pediatric footprint expanded to 47 centers nationwide, including six of the top 10 children’s hospitals per U.S. News & World Report rankings.
- Aquadex therapy platform is FDA-cleared for pediatric and adult patients weighing 20kg+ for fluid overload management.
The big picture
Nuwellis' achievement underscores the growing strategic importance of pediatric care within the cardiorenal sector. The shift towards precision fluid management solutions reflects broader industry trends toward specialized treatments for complex patient demographics. With its Aquadex platform now accounting for half of U.S. revenue, Nuwellis is positioning itself as a key player in high-acuity pediatric care, potentially influencing competitive dynamics and market consolidation.
What we're watching
- Market Penetration
- The pace at which Nuwellis can expand its pediatric footprint beyond the current 47 centers and sustain growth momentum.
- Clinical Adoption
- Whether the inclusion of six top children’s hospitals will drive further institutional adoption and repeat utilization within established programs.
- Regulatory Compliance
- How Nuwellis navigates ongoing FDA requirements for its Aquadex therapy platform, particularly in high-acuity pediatric use cases.
Related topics